Progress of study on PML in cancer stem cell of hematologic malignancies.
10.7534/j.issn.1009-2137.2013.03.050
- Author:
Hong-Ying ZHAO
1
;
Hui-Min LI
Author Information
1. Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Yunnan Province, China.
- Publication Type:Journal Article
- MeSH:
Hematologic Neoplasms;
blood;
Humans;
Neoplastic Stem Cells;
Nuclear Proteins;
Promyelocytic Leukemia Protein;
Transcription Factors;
Tumor Suppressor Proteins
- From:
Journal of Experimental Hematology
2013;21(3):796-800
- CountryChina
- Language:Chinese
-
Abstract:
The promyelocytic leukemia protein (PML), encoded by PML gene, plays a tumor suppressor in acute promyelocytic leukemia and other hematologic malignancies. Recent evidence indicates that PML involves in regulating multiple cell biological function, regulates self-renewal and maintains stable function in stem cell/cancer stem cell of multiple tissues, leading to drug resistance of cancer. This review summarizes the latest research advances about the relationship and therapeutic options between PML and cancer stem cell of hematologic neoplasms, aiming to propose a new avenue for blood cancer treatment.
